Major Response to Imatinib Mesylate in KIT-Mutated Melanoma
Top Cited Papers
- 20 April 2008
- journal article
- case report
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 26 (12) , 2046-2051
- https://doi.org/10.1200/jco.2007.14.0707
Abstract
No abstract availableThis publication has 19 references indexed in Scilit:
- L576P KIT mutation in anal melanomas correlates with KIT protein expression and is sensitive to specific kinase inhibitionInternational Journal of Cancer, 2007
- Gastrointestinal stromal tumourThe Lancet, 2007
- Primary mucosal melanomaJournal of the American Academy of Dermatology, 2007
- Somatic Activation of KIT in Distinct Subtypes of MelanomaJournal of Clinical Oncology, 2006
- Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trialThe Lancet, 2004
- Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal TumorsNew England Journal of Medicine, 2002
- KIT Mutations Are Common in Incidental Gastrointestinal Stromal Tumors One Centimeter or Less in SizeThe American Journal of Pathology, 2002
- Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I studyThe Lancet, 2001
- Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid LeukemiaNew England Journal of Medicine, 2001
- Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cellsNature Medicine, 1996